Literature DB >> 32181676

The Expression, Clinicopathologic Characteristics, and Prognostic Value of Androgen Receptor in Breast Cancer: A Bioinformatics Analysis Using Public Databases.

Wen-Fen Fu1, Juan-Juan Li2, Shao-Hong Kang1, Chuan-Gui Song1.   

Abstract

The role of androgen receptor (AR) in breast cancer has been unveiled in succession for the past few years. In this study, we conducted a comprehensive analysis based on four online public databases of data from many previous studies. We found that the expression of AR is significantly related to age, histological grade, and subtype but not to lymph node status. The low expression level of AR is strongly associated with poor recurrence-free survival, especially with poor distance metastasis-free survival in luminal A patients, but inverse in HER2 (human epidermal growth factor receptor-2) enriched patients. AR might be a biomarker of chemosensitivity in the basal subtype. Besides, the expression of melanophilin (MLPH) is distinctly in accordance with that of AR. AR could play diverse roles in different subtypes of breast cancer.

Entities:  

Keywords:  AR; MLPH; bioinformatics analysis; breast cancer; prognostic value

Mesh:

Substances:

Year:  2020        PMID: 32181676     DOI: 10.1089/dna.2019.5192

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  2 in total

1.  Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.

Authors:  Hui Yan; Hui Xiao; Jiujun Zhu; Jingyang Zhang; Zhenzhen Liu
Journal:  Cancer Manag Res       Date:  2020-12-10       Impact factor: 3.989

2.  Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy.

Authors:  Jiayi Li; Shuang Zhang; Chen Ye; Qian Liu; Yuanjia Cheng; Jingming Ye; Yinhua Liu; Xuening Duan; Ling Xin; Hong Zhang; Ling Xu
Journal:  J Pers Med       Date:  2022-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.